secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2026-08-06T20:10:58+00:00
Accession:  0001193125-26-338009
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q2 2026 revenue $1.4M, cash $330.3M; Varseta-M registrational study planned for 1H 2027
--------------------------------------------------------------------------------

- Revenue $1.4M vs $18.7M YoY, driven by completion of BMS collaboration and lower Astellas activity.
- Cash, equivalents and investments $330.3M; plus $37M July Regeneron payment; runway to 2H 2028.
- Varseta-M Phase 1 data update expected end-2026; registrational study in CRC planned for 1H 2027.
- Regeneron collaboration expanded; $37M target selection payment received; potential milestones up to ~$4B.
- Board and leadership strengthened: Dr. Charles Fuchs, Mamata Gokhale, Alejandra Carvajal appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/0001193125-26-338009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-338009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer